Apollon Formularies (AQSE:APOL) Change In Inventory : £0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies Change In Inventory?

Apollon Formularies's change in inventory for the quarter that ended in Jun. 2023 was £0.00 Mil. It means Apollon Formularies's inventory stayed the same from Jun. 2022 to Jun. 2023 .

Apollon Formularies's change in inventory for the fiscal year that ended in Dec. 2021 was £0.00 Mil. It means Apollon Formularies's inventory stayed the same from Dec. 2020 to Dec. 2021 .

Apollon Formularies's Total Inventories for the quarter that ended in Jun. 2023 was £0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Apollon Formularies's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.00.

Apollon Formularies Change In Inventory Historical Data

The historical data trend for Apollon Formularies's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Change In Inventory Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Inventory

Get a 7-Day Free Trial

0.01

-0.01

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
Change In Inventory	Get a 7-Day Free Trial											-	-	-	-	-

Apollon Formularies Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Apollon Formularies (AQSE:APOL) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Apollon Formularies's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 2
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Apollon Formularies's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Apollon Formularies's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.048
	=	0.00

Apollon Formularies Change In Inventory Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.